Loading clinical trials...
Loading clinical trials...
A Multicenter, Phase I/II Trial of Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast Cancer
Conditions
Interventions
Anastrozole
Palbociclib
+2 more
Locations
5
United States
Mount Sinai Beth Israel Comprehensive Cancer Center West
New York, New York, United States
Perlmutter Cancer Center NYU Langone
New York, New York, United States
Mount Sinai West
New York, New York, United States
New York Presbyterian Columbia Irving Comprehensive Cancer Center
New York, New York, United States
New York Presbyterian Weill Cornell Medical Center
New York, New York, United States
Start Date
December 20, 2017
Primary Completion Date
July 31, 2026
Completion Date
December 31, 2026
Last Updated
July 18, 2025
NCT06608446
NCT04389632
NCT07174336
NCT06966700
NCT04895709
NCT05386108
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions